Mateon’s C001- A Global phase 2 study for OT-101 against COVID-19 received cleareence for patient enrollment
On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the regulatory agency of Peru, to initiate the Company’s C001- phase 2 clinical trial of OT-101, a TGF-antisense, for treatment of patients with mild to severe COVID-19 infection.
The study planned to enroll 48 patients in Peru totaling 72 patients study wide.
Tags:
Source: GlobalNewsWire
Credit:
